• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $NUVB

    Nuvation Bio Inc.

    Subscribe to $NUVB
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells , as well as PARP inhibitor to ER-expressing cancer cells. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was incorporated in 2018 and is headquartered in New York, New York.

    IPO Year: 2020

    Exchange: NYSE

    Website: nuvationbio.com

    Peers

    $PRVB
    $GRPH

    Recent Analyst Ratings for Nuvation Bio Inc.

    DatePrice TargetRatingAnalyst
    4/23/2025$6.00Mkt Outperform
    Citizens JMP
    3/27/2024$1.40 → $10.00Hold → Buy
    Jefferies
    3/26/2024$5.00Neutral → Buy
    BTIG Research
    1/6/2023$5.00 → $2.00Buy → Hold
    Jefferies
    8/2/2022$8.00 → $2.50Outperform → Market Perform
    BMO Capital Markets
    8/2/2022Buy → Neutral
    BTIG Research
    5/4/2022$14.00Buy
    H.C. Wainwright
    10/15/2021$16.00Buy
    BTIG Research
    See more ratings

    Nuvation Bio Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Nuvation Bio Inc.

      10-Q - Nuvation Bio Inc. (0001811063) (Filer)

      5/7/25 4:20:58 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Nuvation Bio Inc.

      8-K - Nuvation Bio Inc. (0001811063) (Filer)

      5/7/25 4:15:24 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Nuvation Bio Inc.

      DEF 14A - Nuvation Bio Inc. (0001811063) (Filer)

      4/8/25 4:45:37 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Nuvation Bio Inc.

      8-K - Nuvation Bio Inc. (0001811063) (Filer)

      3/25/25 9:05:15 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3ASR filed by Nuvation Bio Inc.

      S-3ASR - Nuvation Bio Inc. (0001811063) (Filer)

      3/6/25 5:31:24 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Nuvation Bio Inc.

      10-K - Nuvation Bio Inc. (0001811063) (Filer)

      3/6/25 5:13:58 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Nuvation Bio Inc.

      8-K - Nuvation Bio Inc. (0001811063) (Filer)

      3/6/25 5:12:19 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Nuvation Bio Inc.

      8-K - Nuvation Bio Inc. (0001811063) (Filer)

      3/5/25 4:04:04 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - Nuvation Bio Inc. (0001811063) (Filer)

      3/4/25 4:01:35 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Nuvation Bio Inc.

      8-K - Nuvation Bio Inc. (0001811063) (Filer)

      2/12/25 4:05:16 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Nuvation Bio Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Liu Dongfang exercised 20,000 shares at a strike of $1.94 and sold $50,024 worth of shares (20,000 units at $2.50) (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      5/6/25 4:05:06 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Hung David bought $820,220 worth of shares (500,000 units at $1.64), increasing direct ownership by 0.86% to 58,781,054 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      4/8/25 9:30:51 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mashal Robert bought $166,985 worth of shares (100,000 units at $1.67) (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      4/3/25 4:05:07 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF REGULATORY OFFICER Wentworth Kerry

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      3/4/25 6:37:21 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Sjogren Colleen

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      3/4/25 6:36:46 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Sauvage Philippe

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      3/4/25 6:35:56 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF PEOPLE OFFICER Markel Stacy

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      3/4/25 6:35:24 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Makunje Moses

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      3/4/25 6:34:50 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF MEDICAL OFFICER Liu Dongfang

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      3/4/25 6:33:57 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT AND CEO Hung David

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      3/4/25 6:33:16 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Nuvation Bio Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    Nuvation Bio Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    Nuvation Bio Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nuvation Bio Inc.

      SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)

      11/12/24 10:32:11 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Nuvation Bio Inc.

      SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)

      10/18/24 4:15:55 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Nuvation Bio Inc.

      SC 13D - Nuvation Bio Inc. (0001811063) (Subject)

      9/10/24 4:51:38 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Nuvation Bio Inc. (Amendment)

      SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)

      3/26/24 8:15:27 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nuvation Bio Inc. (Amendment)

      SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)

      2/9/24 9:28:33 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Nuvation Bio Inc.

      SC 13G - Nuvation Bio Inc. (0001811063) (Subject)

      1/29/24 5:25:50 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nuvation Bio Inc. (Amendment)

      SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)

      2/14/23 8:52:08 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Nuvation Bio Inc. (Amendment)

      SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)

      2/13/23 4:40:55 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Nuvation Bio Inc.

      SC 13G - Nuvation Bio Inc. (0001811063) (Subject)

      2/13/23 12:49:18 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nuvation Bio Inc. (Amendment)

      SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)

      2/9/23 12:01:05 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

      New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) under U.S. Food and Drug Administration (FDA) Priority Review; Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025 Published pooled results from pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib in Journal of Clinical Oncology demonstrating high response rates, durable responses, and a favorable safety profile Strong balance sheet with cash, cash equivalents, and marketable securities of $461.7 million as of March 31, 2025 Company to host a conference call today at 4:30 p.m. ET Nuvation Bio Inc. (NYSE:NUVB), a global oncology company tackling some

      5/7/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Present at The Citizens Life Sciences Conference

      Nuvation Bio Inc. (NYSE:NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at The Citizens Life Sciences Conference on Thursday, May 8, 2025, at 10:00 a.m. ET in New York, NY. A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An archived recording will be available for 90 days following each event. About Nuvation Bio Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment by developing therapies

      5/1/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

      Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET. The U.S. Food and Drug Administration assigned taletrectinib's New Drug Application with a Prescription Drug User Fee Act goal date of June 23, 2025. Investors and the general public are invited to listen to a live webcast of the call at https://investors.nuvationbio.com/investors/. Materials related to the call will

      4/22/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

      Nuvation Bio Inc. (NYSE:NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 10:00 a.m. PT/1:00 p.m. ET in Las Vegas, NV. An audio replay of the fireside chat will be available following the event on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An archived recording will be available for 90 days following the event. About Nuva

      4/2/25 8:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

      Nuvation Bio Inc. (NYSE:NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new nonclinical data for taletrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25–30, 2025 in Chicago, Illinois. Presentation Overview: Title: Taletrectinib, a next generation selective ROS1 inhibitor, inhibits growth of ROS1 wild-type and ROS1-G2032R xenografts Presenter: Hitisha Patel, Ph.D., Director of Research, Nuvation Bio Session Category: Experimental and Molecular Therapeutics Session Title: Kinase and Phosphatase I

      3/25/25 4:45:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

      Nuvation Bio Inc. (NYSE:NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be reported in a mini oral presentation at the European Lung Cancer Congress taking place March 26–29, 2025 in Paris, France. Mini Oral Presentation Overview: Title: Taletrectinib vs crizotinib in ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison Presenter: Misako Nagasaka, M.D., Ph.D., Associate Professor – Division of Hematology and Oncology, UCI Scho

      3/25/25 8:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to the New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC); Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025 Innovent Biologics' commercialization of taletrectinib underway in China after recent line agnostic approval for advanced ROS1+ NSCLC; Nippon Kayaku completed submission of a Marketing Authorization Application (MAA) for taletrectinib in Japan for the same indication Launched an Expanded Access Program (EAP) in the U.S. for taletrectinib for advanced ROS1+ NSCLC in February 2025 Strong balance sheet with cash, cash equivalents

      3/6/25 4:30:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

      Nuvation Bio to receive $150 million in royalty interest financing and $50 million in debt upon U.S. FDA approval of taletrectinib, with access to additional $50 million in debt at the Company's option Proceeds from the royalty interest financing expected to fully fund U.S. commercial launch of taletrectinib Pro forma cash balance expected to fully fund development of current clinical-stage pipeline and create a path to potential profitability without the need for additional fundraising; improves flexibility for opportunistic capital deployment Nuvation Bio Inc. (NYSE:NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced non-d

      3/3/25 8:35:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

      Nuvation Bio Inc. (NYSE:NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, MA. A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An archived recording will be available for 90 days following the event. About Nuvation Bio Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing different

      2/24/25 8:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

      Nuvation Bio Inc. (NYSE:NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access Program (EAP) for taletrectinib in the U.S. for the treatment of patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) when no comparable or satisfactory alternative therapy options are available. "This EAP reflects our unwavering dedication to patients with ROS1-positive NSCLC," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "We are committed to working with the ROS1-positive NSCLC community, and the healthcare providers who serve

      2/3/25 8:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Hung David bought $820,220 worth of shares (500,000 units at $1.64), increasing direct ownership by 0.86% to 58,781,054 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      4/8/25 9:30:51 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mashal Robert bought $166,985 worth of shares (100,000 units at $1.67) (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      4/3/25 4:05:07 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mashal Robert bought $220,000 worth of shares (100,000 units at $2.20) (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      10/10/24 4:33:51 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Cui Xiangmin bought $825,348 worth of shares (277,895 units at $2.97) (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/26/24 4:31:59 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Cui Xiangmin bought $1,492,385 worth of shares (500,000 units at $2.98) (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/25/24 5:45:38 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Blickenstaff Kim D bought $500,089 worth of shares (172,189 units at $2.90) (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/13/24 4:33:29 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Nodelman Oleg bought $6,692,265 worth of shares (5,313,100 units at $1.26) (Amendment)

      4/A - Nuvation Bio Inc. (0001811063) (Issuer)

      9/22/23 3:44:37 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Nodelman Oleg bought $6,692,265 worth of shares (5,313,100 units at $1.26)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      9/21/23 8:08:36 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Nuvation Bio Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on Nuvation Bio with a new price target

      Citizens JMP initiated coverage of Nuvation Bio with a rating of Mkt Outperform and set a new price target of $6.00

      4/23/25 8:17:12 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio upgraded by Jefferies with a new price target

      Jefferies upgraded Nuvation Bio from Hold to Buy and set a new price target of $10.00 from $1.40 previously

      3/27/24 8:16:27 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio upgraded by BTIG Research with a new price target

      BTIG Research upgraded Nuvation Bio from Neutral to Buy and set a new price target of $5.00

      3/26/24 7:48:54 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio downgraded by Jefferies with a new price target

      Jefferies downgraded Nuvation Bio from Buy to Hold and set a new price target of $2.00 from $5.00 previously

      1/6/23 7:52:03 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Nuvation Bio from Outperform to Market Perform and set a new price target of $2.50 from $8.00 previously

      8/2/22 6:27:23 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio downgraded by BTIG Research

      BTIG Research downgraded Nuvation Bio from Buy to Neutral

      8/2/22 6:26:52 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Nuvation Bio with a new price target

      H.C. Wainwright initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $14.00

      5/4/22 7:26:54 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research resumed coverage on Nuvation Bio with a new price target

      BTIG Research resumed coverage of Nuvation Bio with a rating of Buy and set a new price target of $16.00

      10/15/21 7:46:36 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Nuvation Bio with a new price target

      RBC Capital Mkts initiated coverage of Nuvation Bio with a rating of Outperform and set a new price target of $15.00

      4/6/21 8:28:36 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Nuvation Bio with a new price target

      BTIG Research initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $16.00

      3/15/21 8:10:18 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Nuvation Bio Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

      Global leader with proven financial, operational, and commercial expertise joins Nuvation Bio as the company prepares to transition into a commercial-stage organization Nuvation Bio Inc. (NYSE:NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw strategic segments including commercial systems, multicha

      10/7/24 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

      Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting First patient treated in a Phase 1/2 study of NUV-1511, the company's first drug-drug conjugate (DDC) to enter the clinic, for the treatment of various advanced solid tumors Strong balance sheet with cash, cash equivalents, and marketable securities of $597.0 million as of March 31, 2024 Nuvation Bio Inc. (NYSE:NUVB), a late-stage

      5/14/24 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

      Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization by the end of 2025 Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access. "We are t

      3/28/24 8:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

      Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Robert Mashal, M.D. to its Board of Directors. "We are delighted to have Dr. Mashal join our Board of Directors," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "Robert is a seasoned biotech industry veteran and his experience as an investor, operator, and medical oncologist will provide us with valuable insights. We look forward to working with Robert to advance Nuvation's pipeline." "Nuvation Bio is at the forefront of developing therape

      1/8/24 4:10:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

      Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease ("CKD"), today announced the appointments of John M. Maraganore, Ph.D. and Jennifer Fox to its Board of Directors. "We are thrilled to welcome John and Jen to the ProKidney Board. They each have a wealth of experience t

      8/11/22 10:01:18 AM ET
      $AGIO
      $ALNY
      $BEAM
      $KYMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

      Dr. Liu is a clinical leader who brings expertise in the discovery, development, and regulatory approval of oncology therapies worldwide Ms. Wentworth has over two decades of industry experience in domestic and international regulatory and quality affairs Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer. Dr. Liu will lead Nuvation Bio's clinical development team and collaborate with the executive committee to provide strategic directi

      7/18/22 7:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ShouTi Strengthens Board With Appointment of Daniel G. Welch as Chairman

      Accomplished biotechnology executive brings over 40 years of commercial and leadership experience across multinational pharmaceutical and biotechnology companies to ShouTi ShouTi Inc., a clinical-stage biopharmaceutical company replacing biologics with world-class small molecule medicines using advanced computational and structure-based technology, today announced that Daniel Welch has been named Chairman of the company's board of directors. "It is a true privilege to welcome Dan to ShouTi as Chairman of our board," said Raymond Stevens, Ph.D., Chief Executive Officer, ShouTi. "As an industry veteran with an outstanding track record in guiding companies across all stages of development an

      1/20/22 8:00:00 AM ET
      $NUVB
      $RARE
      $SGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business Update

      NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the second quarter ended June 30, 2021, and provided a business update.   "The second quarter of 2021 marked multiple achievements for Nuvation Bio. With the appointment of David C. Hanley, Ph.D., as Chief Technical Operations Officer, we are advancing our supply chain, product development and manufacturing efforts. For our pipe

      8/12/21 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Appoints David C. Hanley, Ph.D., as Chief Technical Operations Officer

      NEW YORK, June 1, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David C. Hanley, Ph.D., as Chief Technical Operations Officer, joining the Company's executive management team. In his new role, Dr. Hanley will oversee all early- and late-stage pharmaceutical development and operations, including supply chain, product development and manufacturing efforts, and work closely on commercial planning with Quality, Regulatory Affairs, Clinical Development and Clinical Operations teams.

      6/1/21 7:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Nuvation Bio Inc. Financials

    Live finance-specific insights

    See more
    • Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

      New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) under U.S. Food and Drug Administration (FDA) Priority Review; Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025 Published pooled results from pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib in Journal of Clinical Oncology demonstrating high response rates, durable responses, and a favorable safety profile Strong balance sheet with cash, cash equivalents, and marketable securities of $461.7 million as of March 31, 2025 Company to host a conference call today at 4:30 p.m. ET Nuvation Bio Inc. (NYSE:NUVB), a global oncology company tackling some

      5/7/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

      Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET. The U.S. Food and Drug Administration assigned taletrectinib's New Drug Application with a Prescription Drug User Fee Act goal date of June 23, 2025. Investors and the general public are invited to listen to a live webcast of the call at https://investors.nuvationbio.com/investors/. Materials related to the call will

      4/22/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

      Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Acquisition adds taletrectinib, a next-generation, potentially best-in-class ROS1 inhibitor with Breakthrough Therapy Designations currently completing two pivotal studies for the treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC) Acquisition also adds safusidenib, a potentially best-in-class mutant IDH1 inhibitor currently being evaluated in a global Phase 2 study of patients with grades 2 and 3 IDH1-mutant glioma All-stock transaction preserves Nuvation Bio's robust cash balance and enables development of both new

      3/25/24 7:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business Update

      NEW YORK, March 11, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the year ended December 31, 2020 and provided a business update. "Nuvation Bio began a new chapter as a public company following the successful completion of our business combination with Panacea in February. With a strong cash position of approximately $830 million after transaction fees, as well as a recently expanded leadership team and employees dedicated to meaningfully improving the survival and quality of life for people with canc

      3/11/21 5:15:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care